Interim 18 F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review

Cremonesi, Marta; Garibaldi, Cristina; Timmerman, Robert; Ferrari, Mahila; Ronchi, Sara; Grana, Chiara Maria; Travaini, Laura Lavinia; Gilardi, Laura; Starzyńska, Anna; Ciardo, D.; Orecchia, Roberto; Jereczek‐Fossa, Barbara Alicja; Leonardi, Maria Cristina

doi:10.1016/j.radonc.2017.09.022

Cited by 37 publications

(42 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Esophageal cancer is the sixth leading cause of cancerrelated mortality and the eighth most common cancer in the world. 1 The estimated numbers of incident and mortality cases of esophageal cancer are 477 000 and 375 000 annually in China, respectively. 2 The main histological subtype of esophageal cancer is squamous cell carcinoma (SCC) in East Asia.…”

Section: Introductionmentioning

confidence: 99%

Three‐dimensional conformal radiation therapy alone for esophageal squamous cell carcinoma: 10‐year survival outcomes

Fan

Wu²,

Wang

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

Background Concurrent chemoradiation is the standard treatment for locally advanced esophageal squamous cell carcinoma (SCC). We conducted a phase II study to explore the effect of three‐dimensional conformal radiotherapy (3‐DCRT) alone for patients with locally advanced esophageal SCC. This study aimed to analyze the long‐term survival outcomes. Methods Between November 2004 and April 2007, 30 patients with thoracic esophageal SCC underwent late‐course sequential boost 3‐DCRT at Fudan University Shanghai Cancer Center. The planning target volume (PTV1) comprised a 1.2–1.5 cm lateral margin around the gross tumor volume and a 3.0 cm margin, superior and inferior to the gross tumor volume. PTV2 encompassed the gross tumor volume with a margin of 0.5–0.7 cm. The PTV1 dose delivered was 50 Gy, and the PTV2 dose was a boost dose of 16 Gy, resulting in a total dose of 66 Gy. No chemotherapy was administered. Results The median follow‐up time was 30 months for all patients, and 132 months for patients who were alive. The median overall survival was 27 months (95% confidence interval [CI] 18.9–35.0). The 2‐, 5‐, and 10‐year overall survival rates were 56.6%, 33.3%, and 26.6%, respectively. The median progression‐free survival was 14 months (95% CI 7.7–20.2 months), and the 2‐, 5‐, and 10‐year progression‐free survival rates were 33.3%, 30.0%, and 26.6%, respectively. No severe late toxicity was observed in long‐term survivors. Conclusion Late‐course sequential boost 3‐DCRT is safe and feasible with promising long‐term outcomes for esophageal SCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Three‐dimensional conformal radiation therapy alone for esophageal squamous cell carcinoma: 10‐year survival outcomes

Fan

Wu²,

Wang

et al. 2019

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…This systematic review and meta-analysis will develop on results from previous reviews [13,25] and specifically focus on the response rate and diagnostic accuracy of early PET/CT in oesophageal adenocarcinoma. The findings of this review will inform planning of future clinical trials by demonstrating the proportion of patients that have a response rate after one cycle of neo-adjuvant therapy and clarify the optimum PET threshold used to define this response.…”

Section: Discussionmentioning

confidence: 99%

“…The main advantage of PET/CT is its greater sensitivity for undetected metastases on CT, which changes management in a significant number of patients [12], thus preventing them from undergoing major surgical intervention for little potential benefit. Focus has now been placed on the role of PET/CT to define treatment response, particularly at an early timepoint during neo-adjuvant treatment [13].…”

Section: Neo-adjuvant Chemotherapy Medical Research Council Oe02 and mentioning

confidence: 99%

“…A comprehensive search strategy using text words and controlled vocabulary has been designed using MEDLINE (OVID). (Table 1) The search will be limited to articles published in English from 2005 onwards, because 3D PET became integrated into most PET/CT scanners providing more standardisation in SUVmax from this timepoint onwards [13]. Study filters for randomised control trials and observational study types will be applied.…”

Section: Searches Electronic Searchesmentioning

confidence: 99%

See 1 more Smart Citation

Response rate and diagnostic accuracy of PET/CT during and after neo-adjuvant therapies in oesophageal adenocarcinoma: protocol for a systematic review

Jeffries

Coles

Bradley

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18 F FDG PET/CT)), clinical parameters (e.g. tumour stage) and biomarkers in tumour samples [6,12,17,20,23]. These all have been shown to correlate with treatment outcomes of EC patients to some extent.…”

mentioning

confidence: 99%

Peri-treatment peripheral blood cell score predicts long-term locoregional progression hazard in oesophageal squamous cell carcinoma after definitive chemoradiotherapy

Chen

Guo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Prediction of response to chemoradiotherapy is critical for the optimal management of oesophageal cancer, yet it is still an unmet clinical need. This study aims to evaluate the predictive potential of peri-treatment peripheral blood cells (PBC) in disease progression hazard in oesophageal cancer following chemoradiotherapy.Methods: 87 patients with primary oesophageal squamous cell carcinoma were subjected to definitive concurrent chemoradiotherapy in a phase II trial. PBC parameters (haemoglobin, neutrophils, platelets, lymphocytes and monocytes) were collected at 7 time points through the course of radiotherapy. The values of peri-treatment PBC parameters in predicting 3-year cumulative hazard of tumour progression were evaluated.Results: Patients with disease progression displayed distinct distribution patterns of peri-treatment PBC compared to patients without. Greater prediction capabilities for risk of locoregional disease progression were found in PBC collected after the start of radiotherapy compared to their pretreatment counterparts, and in individual parameters rather than cell-to-cell ratios. The most predictive PBC parameters were integrated by summation and designated as a PBC score (PBCS), which further augmented their predictive power. Patients divided according to their PBCS (high vs medium vs low) had significantly different 3-year cumulative hazards of locoregional progression (58% vs 29% vs 7%, P = 0.0017). Multivariate analysis confirmed that PBCS high (HR 12.2, 95%CI 2.0-76.3, P = 0.007) and medium (HR 5.8, 95%CI 1.2-27.7, P = 0.028) are independent indicators of locoregional progression.Conclusion: Peri-treatment PBCS can predict the long-term hazard of locoregional progression after definitive chemoradiotherapy in patients with oesophageal squamous cell carcinoma.

show abstract

Interim 18 F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review

Cited by 37 publications

References 55 publications

Three‐dimensional conformal radiation therapy alone for esophageal squamous cell carcinoma: 10‐year survival outcomes

Three‐dimensional conformal radiation therapy alone for esophageal squamous cell carcinoma: 10‐year survival outcomes

Response rate and diagnostic accuracy of PET/CT during and after neo-adjuvant therapies in oesophageal adenocarcinoma: protocol for a systematic review

Peri-treatment peripheral blood cell score predicts long-term locoregional progression hazard in oesophageal squamous cell carcinoma after definitive chemoradiotherapy

Contact Info

Product

Resources

About